Pfizer falls on disappointing guidance

Core Insights - Fizer has issued a modest sales guidance for 2026, expecting revenues between $59.5 billion to $62.5 billion, which is largely flat compared to the anticipated $62 billion in sales for 2025 [2] - The profit guidance for 2026 is slightly below market expectations, projected at $2.80 to $3 per share [2] - The company is facing challenges post-COVID, with expected revenue declines from co-products and upcoming patent expirations, estimating a $1.5 billion revenue hit from each factor [3] Financial Performance - Fizer's sales guidance for 2026 is in line with market expectations but indicates stagnation compared to 2025 [2] - The anticipated profit per share for 2026 is lower than what analysts had forecasted [2] - The company expects a total revenue decline of $3 billion due to co-products and patent expirations [3] Strategic Outlook - Analysts suggest that the guidance reflects costs associated with recent acquisitions, such as the obesity biotech Mitsera [4] - Fizer is targeting over $7 billion in cost savings by 2027, which may help mitigate current revenue declines [4] - The company is actively working to overcome revenue challenges stemming from COVID-related impacts and acquisition dilution [5]